DOCSLIB.ORG

Zoom Into Cluster 8 Proteins and Pathways

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Zoom Into Cluster 8 Proteins and Pathways Serotonin (5-HT) receptor G alpha (s) signalling events Glucagon-type ligand receptors Trace amine-associated receptor 1 Amine ligand-binding receptors VasoactiveVasoactive intestinal intestinal polypeptide polypeptide receptor 2 receptor 1 Pituitary adenylate Growthcyclase-activatingGastric hormone-releasing inhibitoryGastric polypeptide inhibitory polypeptide polypeptide receptor hormone receptor Pituitary adenylate cyclase-activating polypeptide type I receptor Glucagon-likeSecretin receptor peptide 2 receptor PhosphodiesteraseFollicle stimulatingProstanoid hormone EP4 receptor receptor 3 Luteinizing hormone/ChoriogonadotropinAmylin receptor AMY1- GCALCR/RAMP1 protein-coupled receptor kinase receptor 6 Adrenomedullin receptor AM1; CALCRL/RAMP2 Adenosine receptors; A2a & A3 PhosphodiesteraseProstanoid DP receptorSerotoninPhosphodiesteraseADM2 44D (5-HT4) 7A receptor Surfactant metabolism Prostanoid IP receptor ADM NGF-independant TRKA activation VasopressinCalcitoninRelaxin V2 receptor gene-related receptor 1 peptide type 1 receptor Adenosine A2 receptor CalcitoninBeta-1 receptor adrenergic receptor Adenosine receptors; A1 & A2a PhosphodiesterasePhosphodiesterasePhosphodiesterase 7B 4A 3B PhosphodiesteraseBeta-3Calcitonin-gene-related adrenergic 11A Phosphodiesterase receptor peptide 10A receptor- CALCRL/RAMP1 Adenosine receptor Adenosine A2a receptor Prostanoid EP2Phosphodiesterase receptor 2A Corticotropin releasingAdrenergicRelaxin factor receptor receptor receptor 2 beta; 2 ADRB1 & ADRB3 PhosphodiesteraseBeta-adrenergic 7 Histamine receptorAmylin kinase receptor H2 2 AMY3;receptor CALCR/RAMP3 Phosphodiesterase 1B Phosphodiesterase- PDE1/PDE5 AdrenomedullinPhosphodiesterase receptor-PhosphodiesterasePhosphodiesterase AM2; 8A CALCRL/RAMP3 4C 1A Adenosine receptors; A2b & A3 Dopamine SerotoninD1 receptor 6 (5-HT6)Dopamine D5 receptorreceptor Phosphodiesterase 3A PhosphodiesterasePhosphodiesteraseSerotonin 8 7Phosphodiesterase (5-HT7) 4B receptor 8B G-protein coupled bile acid receptor 1 Adenosine A2b receptorPhosphodiesteraseCalcitoninThyroid gene-related Phosphodiesterase;stimulating 4 peptidehormone 1PDE3receptor & PDE4 Guanine nucleotide-binding protein G(s)- subunit alpha Dopamine receptor Brain adenylate cyclase 1 Adenylate cyclase type II G alpha (i) signalling events Adenylate cyclase type IX Guanine nucleotide-binding protein G(i)- alpha-1 subunit Glucagon receptor Class A/1 (Rhodopsin-like receptors) Glucagon-likeGuanine nucleotide-binding peptide 1 receptor protein G(k)- alpha-3 subunit Melanocortin receptor 1 MelanocortinMelanocortin receptor 2 receptor 5 Melanocortin receptor (M1 and M4) Adenylate cyclase Alpha-2c MelanocortinadrenergicMelanocortin receptor receptorNeurotrophic receptor 3 tyrosine 4 kinase receptor type 2 Adenylate cyclase type V Hedgehog 'off' state Alpha-2aAdrenergic adrenergic receptor alpha-2 receptor Melatonin receptor 1B Glucagon 2-oxoglutarate receptor 1 Melatonin receptor 1A Pepsin A Cathepsin H CannabinoidCannabinoidN-arachidonyl CB2 receptor CB1 glycine receptor receptor Serotonin 5aOxoeicosanoidSerotonin (5-HT5a) 1f (5-HT1f) receptor receptor 1 Dopamine receptors;C-X-C chemokineD2 & D4G-protein receptor type 7 activation Cannabinoid receptor C-C chemokine receptorTaste type receptor 3 type 2 member 31 G-proteinHydroxycarboxylic coupled receptor acid 55 receptor 2 DopamineLong-wave-sensitiveDopamine D4 receptors; receptorBBSome-mediated opsin D3 1 & D4 cargo-targeting to cilium C-C chemokineHM74 nicotinic acid GPCR receptor type 8 Succinate receptor 1 C-X-CC-C chemokineAlpha-2b chemokine receptor adrenergic typereceptor 3 receptortype 6 G-proteinMelatonin coupled receptor receptor 39 Dopamine D3 receptor C-X-C chemokineC-C Relaxin-3 chemokineMetabotropicreceptor receptor glutamate 1type receptor receptor 5 6 type 4 GABA-B receptor 1 AdenosineStromal cell-derived A1 factor receptor 1 Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding G-protein coupled receptor 35 PurinergicHistamine receptor P2Y14 H3 receptor PyrimidinergicSerotonin 1e (5-HT1e) receptor receptor P2Y4 Peptide ligand-binding receptorsG-protein coupled receptor ChemR23 Regulator of G-protein signalingG-protein 12 coupled receptor 81 AdenosineSomatostatinSerotonin A3 receptor1receptor receptors;G protein-coupled 3 5-HT1B & 5-HT1D receptor 44 Purinergic receptor P2Y11 G-protein coupled receptor 183 Regulator of G-proteinDopamine signalingHistamine PurinergicD2 8 receptor H4 receptor receptor P2Y12 Sphingosine 1-phosphate receptor Edg-6 C-X-CSomatostatin chemokineSerotoninSerotonin receptor 1d Gtypereceptor (5-HT1d) protein-coupled 41a (5-HT1a) receptor receptor receptor kinase 5 Metabotropic glutamate receptorMetabotropic 3 glutamate receptor 7 Lysosphingolipid and LPA receptors Sphingosine 1-phosphate receptor Edg-8 MetabotropicC-C chemokine glutamate receptorC-CG-protein chemokine type 7 coupledreceptor receptor receptor type 92 kinase 2 Sphingosine 1-phosphate receptor Edg-3 NeuropeptideSerotoninProstanoid S EP3receptor 1b receptor (5-HT1b) receptor Apelin receptor ProenkephalinC-X-C chemokine B receptor type 6 Guanine nucleotide-binding protein G(o)- alpha subunit 1 Sphingosine 1-phosphateAngiotensin receptor II G-proteintype 2coupled Metabotropic Edg-5(AT-2) estrogen receptor receptorRelaxin-3 1 glutamate receptor 2 receptor 4 Dopamine receptors;Metabotropic D2 & D3glutamate receptor 8 Apelin GalaninNeuropeptide receptor 1 Y receptorGABA-B receptortype 2 NeuropeptidesNeuropeptide B/W receptorGalanin Y receptor type 1 Regulatorreceptor type 5 of 3 G-protein signaling 4 SomatostatinSomatostatin receptor 1 receptor 4 SomatostatinKappa receptor opioidSomatostatin 5 receptor receptor 2 Melanin-concentratingNociceptin receptor hormone receptor 1 Muscarinic acetylcholine receptorMelanin-concentrating M2 hormoneNeuropeptide receptor Y receptor type 4 Neuropeptide Y receptor type 1 Interleukin-8 receptor B Cannabinoid CB1 receptor/orexinMuscarinic receptor 1 acetylcholinecomplex receptor M4 Galanin receptor 2 Interleukin-8 receptor A Adenylate cyclase type 10 Lysophosphatidic acid receptor Edg-4 Opioid Signalling Interleukin-8 receptors- CXCR1/CXCR2 LysophosphatidicLysophosphatidic acid receptor acid receptorEdg-7 Edg-2 Opioid receptors; mu/kappa/delta Melanin-concentrating hormone receptor 2 Angiotensin II receptor Purinergic receptor P2Y2 Muscarinic acetylcholine receptors Lysophosphatidic acid receptorBradykinin 5 B1 receptor Opioid receptors; mu & delta Bradykinin B2 receptor Opioid receptors; mu & kappa Neuromedin-UNeuromedin-U receptor receptor 1 2 Muscarinic acetylcholineG-protein receptors; coupled M2 & receptor M3 4 Mu opioid receptor Lipoxin A4 receptor Probable G-protein coupled receptor 132 MuscarinicMuscarinic acetylcholine acetylcholine receptor receptors; M1 & M2 Uracil nucleotide/cysteinyl leukotriene receptor Calcium sensing receptor Endothelin-converting enzyme 1 Endothelin-converting enzyme 2 Prolactin-releasing peptide receptor CCR5/mu opioid receptor complex GastrinCholecystokinin releasing peptide Areceptor receptor Neurotensin receptorGhrelin 1 receptor Neuromedin B receptor Sphingosine 1-phosphate receptor Edg-1 MotilinMetastin receptor receptor Orexin and neuropeptides FF and QRFP bind to their respective receptors Proteinase-activatedUrotensin II receptorNeurotensin receptor receptor 2 Endothelin receptor ET-A fMet-Leu-Phe receptor 1/2 Muscarinic acetylcholine receptorEndothelinThyrotropin-releasing M5 receptor- ET-A/ET-B hormone receptor Muscarinic acetylcholine receptor M1/M5 Bombesinchimeric receptor protein Prokineticinsubtype-3 receptor 2 Formyl peptide receptor 1 Muscarinic acetylcholine receptorType-1 angiotensin M1 II receptorAdrenergic receptor alpha Platelet activating factor receptor Endothelin receptor ET-B MuscarinicMuscarinic acetylcholine acetylcholine receptor M1 and receptor M3 ProkineticinNeurotensin M3 receptor receptor 1 2 Glycoprotein hormones alpha chain G alpha (q) signalling events Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Proteinase activated receptor 4 Neuropeptide FF receptor 2 Orexin receptor 2 C-C chemokine receptor type 1 Neuropeptide FF receptor 1 C-C chemokine receptor type 5 Pyroglutamylated RFamide peptide receptor C-C chemokineC-C motif receptor chemokine type 5 2 Zinc finger protein GLI2 LysophosphatidicProstanoid FP receptor acid receptor 4 Potassium voltage-gated channel subfamily B member 1 Vasopressin V1b receptor Orexin receptor 1 Serotonin 2a (5-HT2a) receptor OxytocinNeurokinin Pyrimidinergicreceptor 1 receptor P2Y6 HistamineLeukotrieneFreeCysteinyl B4 fatty receptorH1 acidNeurokinin leukotriene receptor1 31receptor receptor SerotoninPutativeGonadotropin-releasing P2Y2cLysophosphatidic purinoceptor (5-HT2c)Metabotropic 10 hormone acidglutamate receptor receptor receptor receptor 6 5 CysteinylLeukotrieneSerotoninMetabotropic leukotrieneB4Neurokinin glutamate receptor 2b (5-HT2b)receptor 2 1 receptor2 receptor receptor 1 Cysteinyl leukotriene receptor 2 PhospholipaseLeukotrieneProstanoidVasopressin B4 C-beta-3 receptorEP1 receptor V1 receptor Serotonin 2 (5-HT2) receptor VasopressinFree fattyFree V1a acidfatty receptoracid receptor receptor 2 3 Interleukin-8 Mineralocorticoid biosynthesis Androgen biosynthesis 3-beta-hydroxysteroid3-beta-hydroxysteroid dehydrogenase/delta dehydrogenase/delta 5-->4-isomerase5-->4-isomerase type I type II Steroid 5-alpha-reductase 1 Cytochrome P450 11B2 Estradiol 17-beta-dehydrogenase 3 Cytochrome P450 21 Steroid 5-alpha-reductase 2 Estradiol 17-beta-dehydrogenase 12 Rap guanineRap nucleotide guanine nucleotide exchange exchange factor factor 4 3 Glucocorticoid biosynthesis Cytochrome P450 17A1 Alpha-1a adrenergicAdrenergic receptor alpha-1receptor Alpha-1d adrenergicThromboxane A2 receptor receptor Alpha-1b adrenergic receptor Cytochrome P450 11B1 Alpha adrenergic receptor (1a and 1d) 11-beta-hydroxysteroid dehydrogenase 2 Adrenergic receptors; alpha-1 A & B 11-beta-hydroxysteroid dehydrogenase 1 C-C motif chemokine 2 Immunoglobulin epsilon Fc receptor Cyclooxygenase Interleukin-10 signaling.
Load more

Recommended publications
  • Strategies to Increase ß-Cell Mass Expansion
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents .................................................................................................
    [Show full text]
  • Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression
    Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder.
    [Show full text]
  • Bone-Specific Master Transcription Factor Runx2 Regulates Signaling and Metabolism Related Programs in Osteoprogenitors
    ISSN 0233-7657. Biopolymers and Cell. 2010. Vol. 26. N 4 Bone-specific master transcription factor Runx2 regulates signaling and metabolism related programs in osteoprogenitors N. M. Teplyuk1, 2, V. I. Teplyuk2 1University of Massachusetts Medical School 55, Lake Ave North, 01655, Worcester, MA, USA 2Institute of Molecular Biology and Genetics of National Academy of Sciences of Ukraine 150, Zabolotnogo str., Kiev, Ukraine, 03680 [email protected] Aim. Runx2 (AML3) transcription factor is the key regulator of osteoblastic lineage progression and is indispensable for the formation of mineral bones. Runx2 expression increases during differentiation of osteoblasts to induce osteoblast-specific genes necessary for the production and deposition of bone mineral matrix. However, Runx2 is also expressed at a lower level in early osteoprogenitors, where its function is less understood. Here we study how Runx2 determines the early stages of osteoblastic commitment using the model system of Runx2 re-introduction in mouse calvaria cells with Runx2 null background. Method. Affymetrix analysis, Western blot analysis and quantitative real-time reverse transcriptase PCR (qRT-PCR) analysis were employed. Results. Gene expression profiling by Affymetrix microarrays revealed that along with the induction of extracellular matrix and bone mineral deposition related phenotypic markers, Runx2 regulates several cell programs related to signaling and metabolism in the early osteoprogenitors. Particularly, Runx2 regulates transcription of genes involved in G-protein coupled signaling network, FGF and BMP/TGF beta signaling pathways and in biogenesis and metabolism pathways of steroid hormones. Conclusion. The data indicate that the lineage specific program, regulated by the master regulatory transcription factor, includes the regulation of cellular signaling and metabolism which may allow the committed cell to react and behave differently in the same microenvironment.
    [Show full text]
  • Multiplex Gpcr Internalization Assay Using Reverse Transduction on Adenoviral Vector Immobilized Microparticles S
    MULTIPLEX GPCR INTERNALIZATION ASSAY USING REVERSE TRANSDUCTION ON ADENOVIRAL VECTOR IMMOBILIZED MICROPARTICLES S. Han1,2, H.J. Bae1,2, W. Park3 and S. Kwon1,2* 1Department of Electrical and Computer Engineering, Inter-university Semiconductor Research Center (ISRC), Seoul National University, SOUTH KOREA 2Center for Nanoparticle Research, Institute for Basic Science (IBS), SOUTH KOREA and 3Department of Electronics and Radio Engineering, Institute for Laser Engineering, Kyung Hee University, SOUTH KOREA ABSTRACT We present a new multiplexing method for high-throughput cell-based assays in a microtiter well based on reverse transduction of cells by adenoviral vectors immobilized on encoded microparticles. Our particle-based approach spatially confines the gene delivery to cells seeded on the particles and provides the code for identifying the delivered gene, thus easily achieving a multiplex cell microarray in a microtiter well by means of a single pipetting without the cross- expression of genes and the positional identification. Utilizing this method with adenoviral vectors having a G-protein coupled recpeptor (GPCR) gene, we demonstrated 3-plex GPCR internalization assay. KEYWORDS: Multiplex GPCR assay, Reverse transduction, Adenovirus, Encoded microparticle INTRODUCTION G-protein coupled receptors (GPCRs) in the cell membrane are major drug targets in pharmaceutical industry since they interact with a huge variety of endogenous ligands and trigger intracellular functions related to many physiological processes or diseases [1]. Many cell-based assay strategies have been developed to identify GPCR-targeted drugs with more biologically relevant data. Since typical cell-based assays are performed in the microtiter wells and it allows only one type of receptor for each well, multiplex cellular assay technologies have emerged to run high-throughput compound screening with over several hundreds of GPCRs.
    [Show full text]
  • Molecular Mechanisms Involved Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2010 Molecular Mechanisms Involved Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis Ryan Fassnacht Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Physiology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2246 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Ryan C. Fassnacht 2010 All Rights Reserved Molecular Mechanisms Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University. by Ryan Christopher Fassnacht, B.S. Hampden Sydney University, 2005 M.S. Virginia Commonwealth University, 2010 Director: Valeria Mas, Ph.D., Associate Professor of Surgery and Pathology Division of Transplant Department of Surgery Virginia Commonwealth University Richmond, Virginia July 9, 2010 Acknowledgement The Author wishes to thank his family and close friends for their support. He would also like to thank the members of the molecular transplant team for their help and advice. This project would not have been possible with out the help of Dr. Valeria Mas and her endearing
    [Show full text]
  • Mechanisms of Acetylcholine Receptor Loss in Myasthenia Gravis
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.43.7.601 on 1 July 1980. Downloaded from Journal of Neurology, Neurosurgery, and Psychiatry, 1980, 43, 601-610 Mechanisms of acetylcholine receptor loss in myasthenia gravis DANIEL B DRACHMAN, ROBERT N ADAMS, ELIS F STANLEY, AND ALAN PESTRONK From the Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA SUMMARY The fundamental abnormality affecting the neuromuscular junctions of myasthenic patients is a reduction of available AChRs, due to an autoimmune attack directed against the receptors. Antibodies to AChR are present in most patients, and there is evidence that they have a predominant pathogenic role in the disease, aided by complement. The mechanism of antibody action involves acceleration of the rate of degradation of AChRs, attributable to cross-linking of the receptors. In addition, antibodies may block AChRs, and may participate in producing destructive changes, perhaps in conjunction with complement. The possibility that cell-mediated mechanisms may play a role in the autoimmune responses of some myasthenic patients remains to be explored. Although the target of the autoimmune attack in myasthenic patients is probably always the acetyl- Protected by copyright. choline receptors, it is not yet clear which of these immune mechanisms are most important. It is likely that the relative role of each mechanism varies from patient to patient. One of the goals of future research will be to identify the relative importance of each
    [Show full text]
  • Galanin Stimulates Cortisol Secretion from Human Adrenocortical Cells
    859-864 9/11/07 11:36 Page 859 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 20: 859-864, 2007 859 Galanin stimulates cortisol secretion from human adrenocortical cells through the activation of galanin receptor subtype 1 coupled to the adenylate cyclase-dependent signaling cascade ANNA S. BELLONI1, LUDWIK K. MALENDOWICZ2, MARCIN RUCINSKI2, DIEGO GUIDOLIN1 and GASTONE G. NUSSDORFER1 1Department of Human Anatomy and Physiology, School of Medicine, University of Padua, I-35121 Padua, Italy; 2Department of Histology and Embryology, Poznan School of Medicine, PL-60781 Poznan, Poland Received September 10, 2007; Accepted October 5, 2007 Abstract. Previous studies showed that galanin receptors are Introduction expressed in the rat adrenal, and galanin modulates gluco- corticoid secretion in this species. Hence, we investigated the Galanin is a regulatory peptide (30 amino acid residues in expression of the various galanin receptor subtypes (GAL-R1, humans) originally isolated from pig intestine (1) which is GAL-R2 and GAL-R3) in the human adrenocortical cells, and widely distributed in the central and peripheral nervous the possible involvement of galanin in the control of cortisol system, where it acts as a neurotransmitter/neuromodulator. secretion. Reverse transcription-polymerase chain reaction In the gut, galanin modulates insulin release and intestine detected the expression of GAL-R1 (but not GAL-R2 and contractility (2,3). Galanin acts through three distinct subtypes GAL-R3) in the inner zones of the human adrenal cortex. The of G protein-coupled receptors, referred to as GAL-R1, GAL-R2 galanin concentration dependently enhanced basal, but not and GAL-R3 (4). ACTH-stimulated secretion of cortisol from dispersed inner Evidence suggests that galanin is involved in the functional adrenocortical cells (maximal effective concentration, 10-8 M).
    [Show full text]
  • Protease Effects on the Structure of Acetylcholine Receptor Membranes from Torpedo Californica
    PROTEASE EFFECTS ON THE STRUCTURE OF ACETYLCHOLINE RECEPTOR MEMBRANES FROM TORPEDO CALIFORNICA MICHAEL W. KLYMKOWSKY, JOHN E . HEUSER, and ROBERT M. STROUD From the Department of Biochemistry & Biophysics, University of California at San Francisco, San Francisco, California 94143 . Dr . Klymkowsky's present address is MRC Neuroimmunology Project, Department of Zoology, University College London, London WC IE, 6BT, England ABSTRACT Protease digestion of acetylcholine receptor-rich membranes derived from Torpedo californica electroplaques by homogenization and isopycnic centrifugation results in degradation of all receptor subunits without any significant effect on the appearance in electron micrographs, the toxin binding ability, or the sedimentation value of the receptor molecule . Such treatment does produce dramatic changes in the morphology of the normally 0.5- to 2-lm-diameter spherical vesicles when observed by either negative-stain or freeze-fracture electron microscopy . Removal of peripheral, apparently nonreceptor polypeptides by alkali stripping (Neubig et al ., 1979, Proc. Natl. Acad. Sci. U. S. A. 76:690-694) results in increased sensitivity of the acetylcholine receptor membranes to the protease trypsin as indicated by SDS gel electrophoretic patterns and by the extent of morphologic change observed in vesicle structure . Trypsin digestion of alkali-stripped receptor membranes results in a limit degradation pattern of all four receptor subunits, whereupon all the vesicles undergo the morphological transformation to minivesicles
    [Show full text]
  • Interplay Between Gating and Block of Ligand-Gated Ion Channels
    brain sciences Review Interplay between Gating and Block of Ligand-Gated Ion Channels Matthew B. Phillips 1,2, Aparna Nigam 1 and Jon W. Johnson 1,2,* 1 Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA; [email protected] (M.B.P.); [email protected] (A.N.) 2 Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA * Correspondence: [email protected]; Tel.: +1-(412)-624-4295 Received: 27 October 2020; Accepted: 26 November 2020; Published: 1 December 2020 Abstract: Drugs that inhibit ion channel function by binding in the channel and preventing current flow, known as channel blockers, can be used as powerful tools for analysis of channel properties. Channel blockers are used to probe both the sophisticated structure and basic biophysical properties of ion channels. Gating, the mechanism that controls the opening and closing of ion channels, can be profoundly influenced by channel blocking drugs. Channel block and gating are reciprocally connected; gating controls access of channel blockers to their binding sites, and channel-blocking drugs can have profound and diverse effects on the rates of gating transitions and on the stability of channel open and closed states. This review synthesizes knowledge of the inherent intertwining of block and gating of excitatory ligand-gated ion channels, with a focus on the utility of channel blockers as analytic probes of ionotropic glutamate receptor channel function. Keywords: ligand-gated ion channel; channel block; channel gating; nicotinic acetylcholine receptor; ionotropic glutamate receptor; AMPA receptor; kainate receptor; NMDA receptor 1. Introduction Neuronal information processing depends on the distribution and properties of the ion channels found in neuronal membranes.
    [Show full text]
  • Histamine Receptors
    Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity.
    [Show full text]
  • Accelerated Resensitization of the D 1 Dopamine Receptor-Mediated
    The Journal of Neuroscience, October 1994, 74(10): 6260-6266 Accelerated Resensitization of the D 1 Dopamine Receptor-mediated Response in Cultured Cortical and Striatal Neurons from the Rat: Respective Role of CY1 -Adrenergic and /U-methybaspartate Receptors Fabrice Trovero, Philippe Marin, Jean-PO1 Tassin, JoQl Premont, and Jacques Glowinski INSERM U 114, Chaire de Neuropharmacologie, College de France, 75231 Paris Cedex, France As previously shown in vivo, noradrenergic and glutama- cortex. In the rat, bilateral electrolytic lesions of the mesence- tergic neurons can regulate the denervation supersensitivity phalic ventral tegmental area induce a complex and permanent of Dl dopaminergic (DA) receptors in the rat prefrontal cor- behavioral syndrome characterized by a locomotor hyperactiv- tex and striatum respectively. Therefore, the effects of meth- ity and the incapacity of the animal to focalize its attention (Le oxamine (an al-adrenergic agonist) and glutamate on the Moal et al., 1969). Some of the behavioral deficits observed in resensitization of Dl DA receptors were investigated in cul- the lesioned animals, particularly the locomotor hyperactivity, tured cortical and striatal neurons from the embryonic rat. have been attributed for a large part to the selective destruction In the presence of sulpiride and propranolol, DA stimulated of the cortical dopaminergic (DA) innervation (Tassin et al., the Dl DA receptor-mediated conversion of 3H-adenine into 1978). This locomotor hyperactivity was markedly reduced in 3H-cAMP in both intact cortical and striatal cells and these rats with 6-hydroxydopamine (6-OHDA) lesions,which destroy responses were markedly desensitized in cells preexposed not only the ascendingDA neurons but also the ascendingnor- for 15 min to DA (50 AM).
    [Show full text]
  • Receptor Antagonist (H RA) Shortages | May 25, 2020 2 2 2 GERD4,5 • Take This Opportunity to Determine If Continued Treatment Is Necessary
    H2-receptor antagonist (H2RA) Shortages Background . 2 H2RA Alternatives . 2 Therapeutic Alternatives . 2 Adults . 2 GERD . 3 PUD . 3 Pediatrics . 3 GERD . 3 PUD . 4 Tables Table 1: Health Canada–Approved Indications of H2RAs . 2 Table 2: Oral Adult Doses of H2RAs and PPIs for GERD . 4 Table 3: Oral Adult Doses of H2RAs and PPIs for PUD . 5 Table 4: Oral Pediatric Doses of H2RAs and PPIs for GERD . 6 Table 5: Oral Pediatric Doses of H2RAs and PPIs for PUD . 7 References . 8 H2-receptor antagonist (H2RA) Shortages | May 25, 2020 1 H2-receptor antagonist (H2RA) Shortages BACKGROUND Health Canada recalls1 and manufacturer supply disruptions may be causing shortages of commonly used acid-reducing medications called histamine H2-receptor antagonists (H2RAs) . H2RAs include cimetidine, famotidine, nizatidine and ranitidine . 2 There are several Health Canada–approved indications of H2RAs (see Table 1); this document addresses the most common: gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) . 2 TABLE 1: HEALTH CANADA–APPROVED INDICATIONS OF H2RAs H -Receptor Antagonists (H RAs) Health Canada–Approved Indications 2 2 Cimetidine Famotidine Nizatidine Ranitidine Duodenal ulcer, treatment ü ü ü ü Duodenal ulcer, prophylaxis — ü ü ü Benign gastric ulcer, treatment ü ü ü ü Gastric ulcer, prophylaxis — — — ü GERD, treatment ü ü ü ü GERD, maintenance of remission — ü — — Gastric hypersecretion,* treatment ü ü — ü Self-medication of acid indigestion, treatment and prophylaxis — ü† — ü† Acid aspiration syndrome, prophylaxis — — — ü Hemorrhage from stress ulceration or recurrent bleeding, — — — ü prophylaxis ü = Health Canada–approved indication; GERD = gastroesophageal reflux disease *For example, Zollinger-Ellison syndrome .
    [Show full text]